Genetic polymorphisms of the RGS4 and dorsolateral prefrontal cortex morphometry among first episode schizophrenia patients

Molecular Psychiatry

Volumn 10, Issue 2, 2005, Pages 213-219

  Prasad, K M R ^a   Chowdari, K V ^a   Nimgaonkar, V L ^a   Talkowski, M E ^a   Lewis, D A ^a   Keshavan, M S ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Genetic polymorphisms; MRI; Neuroanatomy; Prefrontal cortex; Psychosis; RGS4; Schizophrenia

Indexed keywords

RGS PROTEIN; RGS4 PROTEIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; AUTOPSY; BRAIN SIZE; CLINICAL ARTICLE; CONTROLLED STUDY; DNA MICROARRAY; FEMALE; GENE EXPRESSION; GENETIC POLYMORPHISM; GRAY MATTER; HUMAN; IMAGING SYSTEM; MALE; MORPHOMETRICS; MOTOR CORTEX; NEUROANATOMY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PREFRONTAL CORTEX; PRIORITY JOURNAL; PSYCHOSIS; RISK FACTOR; SCHIZOPHRENIA; VISUAL CORTEX;

ADULT; FEMALE; HUMANS; MALE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; ORGAN SIZE; POLYMORPHISM, SINGLE NUCLEOTIDE; PREFRONTAL CORTEX; REFERENCE VALUES; RGS PROTEINS; SCHIZOPHRENIA;

EID: 13244255399     PISSN: 13594184     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.mp.4001562     Document Type: Article

References (35)

1. Chowdari KV, Mirnics K, Semwal P, Wood J, Lawrence E, Bhatia T et al. Association and linkage analyses of RGS4 polymorphisms in schizophrenia. Hum Mol Genet 2002; 11: 1373-1380.
2. Mirnics K, Middleton FA, Stanwood GD, Lewis DA, Levitt P. Disease-specific changes in regulator of G-protein signaling 4 (RGS4) expression in schizophrenia. Mol Psychiatry 2001; 6: 293-301.
3. Gold JM, Harvey PD. Cognitive deficits in schizophrenia. Psychiatr Clin North Am 1993; 16: 295-312.
4. Goldman-Rakic PS, Selemon LD. Functional and anatomical aspects of prefrontal pathology in schizophrenia. Schizophr Bull 1997; 23: 437-458.
5. Shenton ME, Dickey CD, Frumin M, McCarley RW. A review of MRI findings in schizophrenia. Schizophr Res 2001; 49: 1-52.
6. Weinberger DR, Berman KF, Zec RF. Physiologic dysfunction of dorsolateral prefrontal cortex in schizophrenia. I. Regional cerebral blood flow evidence. Arch Gen Psychiatry 1986; 43: 114-124.
7. Barch DM, Carter CS, Braver TS, Sabb FW, MacDonald III A, Noll DC et al. Selective deficits in prefrontal cortex function in medication-naive patients with schizophrenia. Arch Gen Psychiatry 2001; 58: 280-288.
8. Selemon LD, Goldman-Rakic PS. The reduced neuropil hypothesis: a circuit based model of schizophrenia. Biol Psychiatry 1999; 45: 17-25.
9. Selemon LD, Rajkowska G, Goldman-Rakic PS. Abnormally high neuronal density in the schizophrenic cortex. A morphometric analysis of prefrontal area 9 and occipital area 17. Arch Gen Psychiatry 1995; 52: 805-818, discussion 819-820.
10. Pierri JN, Chaudry AS, Woo TU, Lewis DA. Alterations in chandelier neuron axon terminals in the prefrontal cortex of schizophrenic subjects. Am J Psychiatry 1999; 156: 1709-1719.
11. Mirnics K, Middleton FA, Marquez A, Lewis DA, Levitt P. Molecular characterization of schizophrenia viewed by microarray analysis of gene expression in prefrontal cortex. Neuron 2000; 28: 53-67.
12. Harrison PJ, Owen MJ. Genes for schizophrenia? Recent findings and their pathophysiological implications. Lancet 2003; 361: 417-419.
13. Brzustowicz LM, Hodgkinson KA, Chow EWnC, Honer WG, Bassett AS. Location of a major susceptibility locus for familial schizophrenia on chromosome 1q21-q22. Science 2000; 288: 678-682.
14. Williams N, Preece A, Spurlock G, Norton N, Williams HJ, McCreadie RG et al. Support for RGS4 as a susceptibility gene for schizophrenia. Biol Psychiatry 2004; 55: 192-195.
15. Morris DW, Rodgers A, McGhee KA, Schwaiger S, Scully P, Quinn J et al. Confirming RGS4 as a susceptibility gene for schizophrenia. Am J Med Genet 2004; 125B: 50-53.
16. Taymans JM, Wintmolders C, Te Riele P, Jurzak M, Groenewegen HJ, Leysen JE et al. Detailed localization of regulator of G protein signaling 2 messenger ribonucleic acid and protein in the rat brain. Neuroscience 2002; 114: 39-53.
17. Tsai G, Passani LA, Slusher BS, Carter R, Baer L, Kleinman JE et al. Abnormal excitatory neurotransmitter metabolism in schizophrenic brains. Arch Gen Psychiatry 1995; 52: 829-836.
18. Tsai G, van Kammen DP, Chen S, Kelley ME, Grier A, Coyle JT. Glutamatergic neurotransmission involves structural and clinical deficits of schizophrenia. Biol Psychiatry 1998; 44: 667-674.
19. Tsai G, Coyle JT. Glutamatergic mechanisms in schizophrenia. Annu Rev Pharmacol Toxicol 2002; 42: 165-179.
20. De Vries L, Zheng B, Fischer T, Elenko E, Farquhar MG. The regulator of G protein signaling family. Annu Rev Pharmacol Toxicol 2000; 40: 235-271.
21. Keshavan MS, Stanley JA, Montrose DM, Minshew NJ, Pettegrew JW. Prefrontal membrane phospholipid metabolism of child and adolescent offspring at risk for schizophrenia or schizoaffective disorder: an in vivo (31)P MRS Study. Mol Psychiatry 2003; 8: 316-323.
22. Pettegrew JW, Keshavan MS, Panchalingam K, Strychor S, Kaplan DB, Tretta MG et al. Alterations in brain high-energy phosphate and membrane phospholipid metabolism in first-episode, drug-naive schizophrenics. A pilot study of the dorsal prefrontal cortex by in vivo phosphorus-31 nuclear magnetic resonance spectroscopy. Arch Gen Psychiatry 1991; 48: 563-568.
23. Prasad KMR, Chowdari KV, Nimgaonkar VL, Lewis DA, Mimics K, Lewitt P et al. RGS4 Gene Polymorphism, cognition, and in vivo neurobiology in first episode schizophrenia. Schizophr Res 2004; 67: 28.
24. 31P-magnetic resonance spectroscopy. Psychiatry Res 1995; 57: 91-100.
25. American Psychiatric Association. Diagnostic & Statistical Manual of Mental Disorders. American Psychiatric Association: Washington, DC, 1994.
26. Gilbert AR, Rosenberg DR, Harenski K, Spencer S, Sweeney JA, Keshavan MS. Thalamic volumes in patients with first-episode schizophrenia. Am J Psychiatry 2001; 158: 618-624.
27. Keshavan MS, Anderson S, Beckwith C, Nash K, Pettegrew JW, Krishnan KR. A comparison of stereology and segmentation techniques for volumetric measurements of lateral ventricles in magnetic resonance imaging. Psychiatry Res 1995; 61: 53-60.
28. Schwarzkopf SB, Olson SC, Coffman JA, Nasrallah HA. Third and lateral ventricular volumes in schizophrenia: support for progressive enlargement of both structures. Psychopharmacol Bull 1990; 26: 385-391.
29. Keshavan MS, Bagwell WW, Haas GL, Sweeney JA, Schooler NR, Pettegrew JW. Changes in caudate volume with neuroleptic treatment. Lancet 1994; 344: 1434.
30. Thaminy S, Auerbach D, Arnoldo A, Stagljar I. Identification of novel ErbB3-interacting factors using the split-ubiquitin membrane yeast two-hybrid system. Genome Res 2003; 13: 1744-1753.
31. Shifman S, Bronstein M, Sternfeld M, Pisante-Shalom A, Lev-Lehman E, Weizman A et al. A highly significant association between a COMT haplotype and schizophrenia. Am J Hum Genet 2002; 71: 1296-1302.
32. Glatt SJ, Faraone SV, Tsuang MT. Association between a functional catechol O-methyltransferase gene polymorphism and schizophrenia: meta-analysis of case-control and family-based studies. Am J Psychiatry 2003; 160: 469-476.
33. Straub RE, Jiang Y, MacLean CJ, Ma Y, Webb BT, Myakishev MV et al. Genetic variation in the 6p22.3 gene DTNBP1, the human ortholog of the mouse dysbindin gene, is associated with schizophrenia. Am J Hum Genet 2002; 71: 337-348.
34. Schwab SG, Knapp M, Mondabon S, Hallmayer J, Borrmann-Hassenbach M, Albus M et al. Support for association of schizophrenia with genetic variation in the 6p22.3 gene, dysbindin, in sib-pair families with linkage and in an additional sample of triad families. Am J Hum Genet 2003; 72: 185-190.
35. Lewis DA, Levitt P. Schizophrenia as a disorder of neurodevelopment. Annu Rev Neurosci 2002; 25: 409-432.